Sarepta Therapeutics | SRPT - Equity Capital And Reserves


Sarepta Therapeutics reported $1.53B in Equity Capital and Reserves for its fiscal quarter ending in September of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.39B 80.88M Sep/2026
Agios Pharmaceuticals USD 979.34M 46.68M Sep/2026
Alnylam Pharmaceuticals USD 3.6B 2.25B Sep/2026
Amgen USD 14.35B 2.66B Sep/2026
BioCryst Pharmaceuticals USD -397.38M 56.9M Sep/2026
Biogen USD 19.04B 194.3M Sep/2026
BioMarin Pharmaceutical USD 6.26B 65.66M Sep/2026
Capricor Therapeutics USD 246.22M 32.48M Jun/2026
Daiichi Sankyo JPY 1.76T 54.94B Sep/2026
Eli Lilly USD 40.27B 6.39B Sep/2026
Gilead Sciences USD 13.04B 1.3B Sep/2026
Incyte USD 5.64B 701.49M Sep/2026
Insmed USD 726.21M 31.28M Sep/2026
Ionis Pharmaceuticals USD 393.64M 46.1M Sep/2026
Moderna USD 6.84B 76M Sep/2026
Nektar Therapeutics USD 576.22M 486.38M Mar/2026
Neurocrine Biosciences USD 3.88B 185.1M Sep/2026
Novavax USD -216.86M 26.15M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
PTC Therapeutics USD -191.21M 25.85M Sep/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 72.88B 3.31B Sep/2026
Sarepta Therapeutics USD 1.53B 1.06M Sep/2026
Tectonic Therapeutic USD 223.85M 6.57M Jun/2026
Ultragenyx Pharmaceutical USD -376M 85M Sep/2026
Vertex Pharmaceuticals USD 20.91B 659.5M Sep/2026